 Azetidines
"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D001384
|
| MeSH Number(s) |
D03.383.082.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2014 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 1 | 2 | | 2024 | 3 | 2 | 5 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Yamazaki S, Kaneko S, Shimbo A, Irabu H, Ogino R, Miyamoto T, Izawa K, Segawa Y, Kakizaki J, Mori M, Shimizu M. Overlapping Aicardi-Goutières and Singleton-Merten syndromes with a heterozygous gain-of-function mutation in IFIH1 mimicking juvenile idiopathic arthritis. Immunol Med. 2025 Sep; 48(3):256-260.
-
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug; 35(8):707-717.
-
Varnet M, Kayani S, Wang C. Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002). Neurology. 2024 Apr 09; 102(7_supplement_1):6859.
-
Gurrea-Rubio M, Wang Q, Mills EA, Wu Q, Pitt D, Tsou PS, Fox DA, Mao-Draayer Y. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NF?B and Mitochondrial Pathways. Int J Mol Sci. 2024 Feb 20; 25(5).
-
Wang LL, Tuohy S, Xu KL, Nace A, Yang R, Zheng Y, Burdick JA, Cotsarelis G. Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts. Adv Healthc Mater. 2024 05; 13(12):e2303256.
-
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374.
-
McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, Nash B, Gillard KK, Ray KK. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs. 2023 Jan; 23(1):67-76.
-
Zehra Okus F, Busra Azizoglu Z, Canatan H, Eken A. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo. Int Immunopharmacol. 2022 Jun; 107:108665.
-
Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. Ann Oncol. 2022 05; 33(5):544-555.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|